IL222775A - Superior efficacy of 37cd antibody in blood samples of chronic lymphocytic leukemia - Google Patents

Superior efficacy of 37cd antibody in blood samples of chronic lymphocytic leukemia

Info

Publication number
IL222775A
IL222775A IL222775A IL22277512A IL222775A IL 222775 A IL222775 A IL 222775A IL 222775 A IL222775 A IL 222775A IL 22277512 A IL22277512 A IL 22277512A IL 222775 A IL222775 A IL 222775A
Authority
IL
Israel
Prior art keywords
antibodies
blood samples
superior efficacy
cll blood
cll
Prior art date
Application number
IL222775A
Other languages
English (en)
Hebrew (he)
Other versions
IL222775A0 (en
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44546328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL222775(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IL222775A0 publication Critical patent/IL222775A0/en
Publication of IL222775A publication Critical patent/IL222775A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL222775A 2010-07-16 2012-10-31 Superior efficacy of 37cd antibody in blood samples of chronic lymphocytic leukemia IL222775A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10169795 2010-07-16
EP10175586 2010-09-07
PCT/EP2011/062133 WO2012007576A1 (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples

Publications (2)

Publication Number Publication Date
IL222775A0 IL222775A0 (en) 2012-12-31
IL222775A true IL222775A (en) 2017-10-31

Family

ID=44546328

Family Applications (1)

Application Number Title Priority Date Filing Date
IL222775A IL222775A (en) 2010-07-16 2012-10-31 Superior efficacy of 37cd antibody in blood samples of chronic lymphocytic leukemia

Country Status (15)

Country Link
US (3) US20120189618A1 (https=)
EP (2) EP2593479A1 (https=)
JP (2) JP2013538790A (https=)
KR (1) KR20130100918A (https=)
CN (2) CN103003309A (https=)
AU (1) AU2011278227B2 (https=)
BR (1) BR112013001012A2 (https=)
CA (1) CA2799036A1 (https=)
CL (1) CL2013000101A1 (https=)
EA (1) EA025365B1 (https=)
IL (1) IL222775A (https=)
MX (1) MX341463B (https=)
NZ (2) NZ703225A (https=)
PH (1) PH12013500118A1 (https=)
WO (1) WO2012007576A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20140196A1 (es) 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
WO2013160396A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
JP2015517511A (ja) 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用
US10294304B2 (en) 2015-04-13 2019-05-21 Pfizer Inc. Chimeric antigen receptors targeting B-cell maturation antigen
US11578115B2 (en) 2017-01-10 2023-02-14 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
CN118599009A (zh) 2017-03-16 2024-09-06 综合医院公司 靶向cd37的嵌合抗原受体
JP7330942B2 (ja) 2017-03-31 2023-08-22 ジェンマブ ホールディング ビー．ブイ． 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法
WO2019243636A1 (en) 2018-06-22 2019-12-26 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
EP3860715A1 (en) 2018-10-04 2021-08-11 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
WO2023057583A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1
AU2024362226A1 (en) 2023-10-18 2026-03-05 Debiopharm International S.A. Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
RU2423381C2 (ru) * 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
JP2010532764A (ja) * 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
PE20140196A1 (es) * 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
RU2531754C2 (ru) * 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
WO2010057047A1 (en) * 2008-11-13 2010-05-20 Trubion Pharmaceutics, Inc. Cd37 immunotherapeutic combination therapies and uses thereof

Also Published As

Publication number Publication date
EP3252077A1 (en) 2017-12-06
WO2012007576A1 (en) 2012-01-19
JP2017019800A (ja) 2017-01-26
US20120189618A1 (en) 2012-07-26
US20150266967A1 (en) 2015-09-24
CL2013000101A1 (es) 2013-12-27
CN105749276A (zh) 2016-07-13
MX2012013613A (es) 2012-12-17
NZ603161A (en) 2015-02-27
MX341463B (es) 2016-08-22
AU2011278227B2 (en) 2017-03-02
EA201201660A1 (ru) 2013-07-30
PH12013500118A1 (en) 2013-03-11
US20130236454A1 (en) 2013-09-12
CA2799036A1 (en) 2012-01-19
JP2013538790A (ja) 2013-10-17
EA025365B1 (ru) 2016-12-30
NZ703225A (en) 2016-11-25
BR112013001012A2 (pt) 2016-05-24
IL222775A0 (en) 2012-12-31
CN103003309A (zh) 2013-03-27
KR20130100918A (ko) 2013-09-12
AU2011278227A1 (en) 2012-11-15
EP2593479A1 (en) 2013-05-22

Similar Documents

Publication Publication Date Title
IL222775A0 (en) Superior efficacy of cd37 antibodies in cll blood samples
IL282877A (en) Low Affinity Blood Marrow Barrier Receptor Antibodies and Uses Therefor
ZA201209390B (en) Comparison of protein samples
EP2665749A1 (en) Anti - il1rap antibodies and their use for treating human
ZA201303175B (en) Human anti-tau antibodies
IL251697A0 (en) Antibodies against 3erbb and their uses
IL250691A0 (en) Anti-ox40 antibodies and methods of using them
AU2016202447A1 (en) Low affinity blood brain barrier receptor antibodies and uses therefor
HUE058226T2 (hu) NGF elleni antitestek és alkalmazásuk
IL252154A0 (en) Anti-dr5 antibodies, compositions comprising the same and uses thereof
ZA201307641B (en) Human tissue factor antibody and uses thereof
EP2638073A4 (en) PROTEIN COMPLEXES FOR ANTIGEN BINDING, AND METHODS OF USE
ZA201208541B (en) Antibody preparations
PT2946791T (pt) Anticorpos anti-cd277 e suas utilizações
EP2598882A4 (en) SAFE AND FUNCTIONAL HUMANIZED ANTIBODIES
PL2621955T3 (pl) Przeciwciała anty-CEACAM6 i ich zastosowania
IL223667B (en) S100a4 antibodies and therapeutic uses thereof
EP2540744A4 (en) TOTALLY HUMAN MONOCLONAL ANTIBODY AGAINST VEGF, PREPARATION METHOD AND APPLICATION THEREOF
EP2598164A4 (en) PERIPHERAL BLOOD SPARC ANTIBODIES AND USES THEREOF
EP2756092A4 (en) METHOD FOR THE PRODUCTION OF CELLS, TISSUE AND ANTIBODIES
IL226635B (en) Human anti-sod1 antibodies
HK1194078A (en) Human tissue factor antibody and uses thereof
HK1186744A (en) Anti-ngf antibodies and their use
HK1193417A (en) Anti-fgfr4 antibodies and methods of use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed